Xie Feng, Liu Nan, Yan Linxuan, Ning Yilin, Lim Ka Keat, Gong Changlin, Kwan Yu Heng, Ho Andrew Fu Wah, Low Lian Leng, Chakraborty Bibhas, Ong Marcus Eng Hock
Programme in Health Services and Systems Research, Duke-NUS Medical School, 8 College Road, 169857, Singapore.
Health Services Research Centre, Singapore Health Services, Singapore.
EClinicalMedicine. 2022 Mar 6;45:101315. doi: 10.1016/j.eclinm.2022.101315. eCollection 2022 Mar.
Emergency readmission poses an additional burden on both patients and healthcare systems. Risk stratification is the first step of transitional care interventions targeted at reducing readmission. To accurately predict the short- and intermediate-term risks of readmission and provide information for further temporal risk stratification, we developed and validated an interpretable machine learning risk scoring system.
In this retrospective study, all emergency admission episodes from January 1st 2009 to December 31st 2016 at a tertiary hospital in Singapore were assessed. The primary outcome was time to emergency readmission within 90 days post discharge. The Score for Emergency ReAdmission Prediction (SERAP) tool was derived via an interpretable machine learning-based system for time-to-event outcomes. SERAP is six-variable survival score, and takes the number of emergency admissions last year, age, history of malignancy, history of renal diseases, serum creatinine level, and serum albumin level during index admission into consideration.
A total of 293,589 ED admission episodes were finally included in the whole cohort. Among them, 203,748 episodes were included in the training cohort, 50,937 episodes in the validation cohort, and 38,904 in the testing cohort. Readmission within 90 days was documented in 80,213 (27.3%) episodes, with a median time to emergency readmission of 22 days (Interquartile range: 8-47). For different time points, the readmission rates observed in the whole cohort were 6.7% at 7 days, 10.6% at 14 days, 13.6% at 21 days, 16.4% at 30 days, and 23.0% at 60 days. In the testing cohort, the SERAP achieved an integrated area under the curve of 0.737 (95% confidence interval: 0.730-0.743). For a specific 30-day readmission prediction, SERAP outperformed the LACE index (Length of stay, Acuity of admission, Charlson comorbidity index, and Emergency department visits in past six months) and the HOSPITAL score (Hemoglobin at discharge, discharge from an Oncology service, Sodium level at discharge, Procedure during the index admission, Index Type of admission, number of Admissions during the last 12 months, and Length of stay). Besides 30-day readmission, SERAP can predict readmission rates at any time point during the 90-day period.
Better performance in risk prediction was achieved by the SERAP than other existing scores, and accurate information about time to emergency readmission was generated for further temporal risk stratification and clinical decision-making. In the future, external validation studies are needed to evaluate the SERAP at different settings and assess their real-world performance.
This study was supported by the Singapore National Medical Research Council under the PULSES Center Grant, and Duke-NUS Medical School.
急诊再入院给患者和医疗系统都带来了额外负担。风险分层是旨在减少再入院的过渡性护理干预措施的第一步。为了准确预测再入院的短期和中期风险,并为进一步的时间风险分层提供信息,我们开发并验证了一种可解释的机器学习风险评分系统。
在这项回顾性研究中,对新加坡一家三级医院2009年1月1日至2016年12月31日期间的所有急诊入院病例进行了评估。主要结局是出院后90天内急诊再入院的时间。急诊再入院预测评分(SERAP)工具是通过基于可解释机器学习的事件发生时间结局系统得出的。SERAP是一个包含六个变量的生存评分,考虑了去年的急诊入院次数、年龄、恶性肿瘤病史、肾脏疾病史、入院时的血清肌酐水平和血清白蛋白水平。
整个队列最终纳入了293,589例急诊入院病例。其中,203,748例纳入训练队列,50,937例纳入验证队列,38,904例纳入测试队列。80,213例(27.3%)病例记录了90天内的再入院情况,急诊再入院的中位时间为22天(四分位间距:8 - 47天)。在不同时间点,整个队列观察到的再入院率在7天时为6.7%,14天时为10.6%,21天时为13.6%,30天时为16.4%,60天时为23.0%。在测试队列中,SERAP的曲线下综合面积为0.737(95%置信区间:0.730 - 0.743)。对于特定的30天再入院预测,SERAP的表现优于LACE指数(住院时间、入院 acuity、Charlson合并症指数和过去六个月内的急诊就诊次数)和HOSPITAL评分(出院时血红蛋白、肿瘤科出院、出院时钠水平、入院期间的手术、入院类型、过去12个月内的入院次数和住院时间)。除了30天再入院外,SERAP还可以预测90天期间任何时间点的再入院率。
SERAP在风险预测方面比其他现有评分表现更好,并生成了关于急诊再入院时间的准确信息,用于进一步的时间风险分层和临床决策。未来,需要进行外部验证研究,以在不同环境中评估SERAP并评估其在现实世界中的表现。
本研究由新加坡国家医学研究理事会的PULSES中心资助以及杜克 - 新加坡国立大学医学院支持。